Omnipod 5 Automated Insulin Delivery System Released in the U.K.

Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in the United Kingdom for individuals aged two years and older with type 1 diabetes (T1D).
 
“Since its commercial launch in the United States, Omnipod 5 has had a remarkable impact on people with diabetes,” Insulet President/CEO Jim Hollingshead said. “Every day, we hear how this experience of Omnipod 5 reduces the burden and improves quality of life for people with diabetes, and we are excited to make a difference in other parts of the world, beginning with the U.K. We are committed to making Omnipod 5 an option for as many people as possible, as quickly as we can, and working hard to secure broad access globally.”
 
Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin delivery and help protect against high and low glucose levels.¹ The system² consists of the tubeless Pod enhanced with SmartAdjust technology and the Omnipod 5 Controller with its integrated SmartBolus Calculator. The system is interoperable with the Dexcom G6 CGM for automated insulin delivery.
 
Every five minutes, SmartAdjust technology receives a CGM value and trend, and predicts where glucose will be 60 minutes into the future. The system then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target. Omnipod 5 simplifies daily diabetes management by making many of these dosing decisions for the user, while the user focuse on other aspects of daily life.
 
Lydia Parkhurst, a 26-year-old geography teacher who enjoys backpacking and has travelled the world with her Omnipod DASH System, has been a Podder since 2015. “I am so excited for the release of Omnipod 5 in the U.K.,” Lydia said. “I can’t wait to experience the freedom of being tubeless while also having the support of hybrid closed loop technology. The combination will make living with type 1 diabetes far less complicated—allowing me to live my life to the fullest.”
 
“With NICE³ set to approve hybrid closed loop in England and Wales later this year, we are delighted that more hybrid closed loop systems such as Omnipod 5 are becoming available to help people manage their type 1 diabetes,” JDRF UK CEO Karen Addington stated. “Diabetes management is very personal, so access to a range of technology options is crucial. A wider choice of hybrid closed loop systems offers people with type 1 diabetes evidence-based treatment they can trust to support them to manage their condition with confidence.”
 
Insulet is working in partnership with the National Health Service (NHS) at all levels to ensure access to Omnipod 5 for people with type 1 diabetes.
 
Insulet plans to release Omnipod 5 in Germany this fall.

Headquartered in Massachusetts, Insulet Corporation is a medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible smartphone or Omnipod 5 Controller. Insulet also leverages the design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. 

References
¹ Study in 240 people with T1D aged 6 to 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. three-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. three-month Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et. al. Diabetes Care (2021). Study in 80 children with T1D aged 2 to 5.9 years involving two weeks of standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in children for standard therapy vs. Omnipod 5 was 38.4% vs. 16.9%. Average day time (6AM-12AM) with high blood glucose in children for standard therapy vs. Omnipod 5 was 39.4% vs. 29.5%. Median overnight time (12AM-6AM) with low blood glucose in children for standard therapy vs. Omnipod 5 was 3.41% vs. 2.13%. Median day time (6AM-12AM) with low blood glucose in children for standard therapy vs. Omnipod 5 was 3.43% vs. 2.46%. Sherr J, et. al. Diabetes Care (2022).
² Integration with the Dexcom G6 CGM is required for automated insulin delivery.
³ National Institute of Health and Care Excellence.